Rabbit Recombinant Monoclonal CD167a/DDR1 antibody. Suitable for Flow Cyt, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Not recommended | Tested |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/600 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Tyrosine kinase that functions as a cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing (By similarity). Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11.
CD167a, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE, DDR1, Epithelial discoidin domain-containing receptor 1, Epithelial discoidin domain receptor 1, CD167 antigen-like family member A, Cell adhesion kinase, Discoidin receptor tyrosine kinase, HGK2, Mammary carcinoma kinase 10, Protein-tyrosine kinase 3A, Protein-tyrosine kinase RTK-6, TRK E, Tyrosine kinase DDR, Tyrosine-protein kinase CAK, MCK-10
Rabbit Recombinant Monoclonal CD167a/DDR1 antibody. Suitable for Flow Cyt, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
CD167a also known as DDR1 (Discoidin Domain Receptor 1) is a receptor tyrosine kinase with a molecular mass of approximately 101 kDa. This protein is expressed widely in various tissues including the thyroid lung kidney and mammary gland. It becomes activated upon collagen binding leading to the regulation of cell adhesion proliferation and extracellular matrix remodeling. The DDR1 protein plays a mechanistic role in responding to unique collagen-rich environments within the body.
CD167a/DDR1 modulates interactions between cells and their surrounding matrix. It is involved in a complex with collagen mediating signal transduction processes. This interaction is important for cellular biophysical responses driving processes like cell migration and differentiation. In marmoset thyroid tissue DDR1 helps maintain structural integrity and regulates cellular activities important for normal thyroid function.
CD167a/DDR1 participates in key signaling pathways including those related to cell adhesion and extracellular matrix remodeling. Specifically it operates within the MAPK/ERK pathway influencing cell cycle dynamics and responses to stress signals. DDR1 also interacts with proteins like SHC and Ras enabling communication between the cell surface and intracellular targets necessary for growth and adaptation.
Mutations or irregular expression of CD167a/DDR1 have implications in cancer and fibrotic diseases. Overexpression or aberration of DDR1 can contribute to tumorigenesis facilitating tumor cell invasion and metastasis. In fibrotic conditions altered DDR1 activity can disrupt normal matrix remodeling linking it to proteins such as collagen I and III which play major roles in these disorders. Understanding DDR1's role offers potential for therapeutic interventions in targeting related pathological conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of HeLa (human cervix adenocarcinoma epithelial cell, Left) / T-47D (human ductal breast epithelial tumor epithelial cell, Right) cells labelling CD167a/DDR1 with ab255810 at 1/600 dilution (Red) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) isotype control (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at 1/2000 dilution was used as the secondary antibody.
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized MCF7 (human breast adenocarcinoma epithelial cell) cells labelling CD167a/DDR1 with ab255810 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary antibody at 1/1000 dilution (Green). Confocal image showing staining in MCF7 cell line. Negative control: HeLa (PMID: 19787223, 24740739) is observed. Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary at 1/1000 2 ug/ml dilution.
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized T-47D (human ductal breast epithelial tumor epithelial cell) cells labelling CD167a/DDR1 with ab255810 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary antibody at 1/1000 dilution (Green). Confocal image showing staining in T-47D cell line is observed. Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary at 1/1000 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com